Investing

RBC names Gilead a top biotech pick based on valuation

A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

David Paul Morris | Bloomberg | Getty Images

Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.

The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.

Articles You May Like

Beauty stocks post major losses after a week of worrying results
Chipotle earnings beat estimates, but stock falls on weak same-store sales forecast
Eaton finds its footing ahead of earnings after DeepSeek fears shook the stock
Ken Griffin’s multistrategy hedge fund at Citadel rose 1.4% in volatile January
Huawei revenue rises at fastest pace since 2016 on the back of consumer segment growth

Leave a Reply

Your email address will not be published. Required fields are marked *